SEC Form 4 · accession 0001209191-18-059061
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Walbert
Officer — Chairman, President and CEO · Director
Period of report
Nov 14, 2018
Accepted (ET)
Nov 16, 2018 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Nov 14, 2018 | M | 104,334 | $5.20 | A | 650,404 | D | |
| Ordinary Shares | Nov 14, 2018 | M | 107,219 | $12.94 | A | 757,623 | D | |
| Ordinary Shares | Nov 14, 2018 | M | 196,794 | $4.96 | A | 954,417 | D | |
| Ordinary SharesF2 | Nov 14, 2018 | S | 408,347 | $21.54 | D | 546,070 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $5.20 | Nov 14, 2018 | M | 104,334 | D | — | Feb 2, 2020 | Ordinary Shares | 104,334 | 0 | D |
| Stock Option (Right to Buy)F3 | $12.94 | Nov 14, 2018 | M | 107,219 | D | — | Jun 15, 2020 | Ordinary Shares | 107,219 | 0 | D |
| Stock Option (Right to Buy)F3 | $4.96 | Nov 14, 2018 | M | 196,794 | D | — | Dec 7, 2021 | Ordinary Shares | 196,794 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.21 to $21.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.